AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 142 min read$JNJ

Duato Joaquin sold $32.2M of JNJ

Duato Joaquin (CEO and Chairman of the Board) sold 123,291 shares of JOHNSON & JOHNSON (JNJ) at an average of $261.17 ($261.00–$262.00, $32.20M total) across 2 trades on 2026-08-13.

Original reporting
SEC EDGAR · Duato Joaquin
Published Aug 14, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JNJ
Neutral
low confidence
Mentioned
$JNJ
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

A CEO open-market sale of roughly $32.2M can create short-term negative optics, but it does not change fundamentals absent accompanying guidance, legal, or operational news.

02

Market read

Traders may monitor for follow-on insider activity or correlate with price/volume, but the filing does not provide new business information.

03

What to watch

No 10b5-1 plan is stated, but the filing alone does not reveal tax, estate, or diversification context, limiting inference quality.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-14, sale executed 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralLow confidence
Context

SEC Form 4 shows CEO and Chairman Duato Joaquin sold 123,291 shares of JNJ for about $32.2M on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and material in size, but insider sales are often pre-planned or diversified and the text provides no new operational or financial information.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may reflect diversification or liquidity needs and does not necessarily signal reduced confidence, especially without evidence of a related negative event.

Key entities

  • issuer
    Johnson & Johnson

    Subject of the Form 4 insider sale disclosure.

  • insider
    Duato Joaquin

    CEO and Chairman of the Board who sold shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JNJ insider trading history →

Related articles

AUG 14
$JNJMed

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

Johnson & Johnson (NYSE:JNJ) agreed to a proposed $5.5B settlement of talc lawsuits alleging its talc products caused ovarian cancer, covering nearly 80,000 claims, according to the company. The article notes a federal judge questioned some expert testimony and disqualified a plaintiffs’ firm. It compares JNJ with AbbVie (NYSE:ABBV) and cites hedge fund and short-interest data.

insidermonkey.com6 min
AUG 12
$JNJMed

140-year-old Dividend King eyes bold update to unlock new growth

Johnson & Johnson (JNJ) plans to spin off its orthopaedics division into a stand-alone company, DePuy Synthes, targeted for completion 18 to 24 months after an Oct. 2025 announcement. JNJ reported Q2 2026 sales of $25.3B, adjusted EPS $2.90, and raised 2026 guidance to $100.8B-$101.4B sales. It also cited a $50B oncology sales target by 2030 and a Dec. 8 Enterprise Business Review.

yahoo.com5 min
AUG 11
$JNJMed

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90, both above estimates, and raised full-year guidance to a $101.1B midpoint and $11.68 adjusted EPS. Medtronic (MDT) posted its fastest annual revenue growth in a decade, with FY26 revenue $36.4B and adjusted revenue $36.3B. Article compares post-earnings positioning and risks.

insidermonkey.com4 min
AUG 10
$JNJMed

This Week’s CGT News: In Vivo CAR T Draws Major Investment

Johnson & Johnson and Sail Biomedicines agreed to develop in vivo CAR T therapies. J&J will pay $785 million upfront, including a $465 million equity investment, with $140 million more for milestones, and has an option to acquire Sail for $2.58 billion. Separately, an FDA advisory committee voted 3-9 against deramiocel for Duchenne cardiomyopathy.

themedicinemaker.com6 min
AUG 10
$JNJMed

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (JNJ) received FDA De Novo authorization for its OTTAVA robotic surgical system and is entering U.S. soft-tissue robotic surgery. OTTAVA is authorized for multiple upper-abdominal procedures, with a selective U.S. launch and an ongoing inguinal hernia trial. The article compares JNJ’s entry with Intuitive Surgical (ISRG) and its da Vinci 5 installed base.

yahoo.com6 min